Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD22 CAR-T for B-cell Malignancies
NCT03262298Phase 2Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Aug 2017
- Primary completion
- Aug 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Anti-CD22 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences) in B cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma, sponsored by Academy of Military Medical Sciences. Status: unknown.
02
Drugs
Anti-CD22 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences)
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT03262298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262298.